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Abstract
Background: Simvastatin, which is used to control elevated cholesterol levels, is one of the most widely prescribed drugs.
However, a daily excessive dose can induce drug-toxicity, especially in muscle and liver. Current markers for toxicity reflect
mostly the late stages of tissue damage; thus, more efficient methods of toxicity evaluation are desired.
Methodology/Principal Findings: As a new way to evaluate toxicity, we performed NMR-based metabonomics analysis of
urine samples. Compared to conventional markers, such as AST, ALT, and CK, the urine metabolic profile provided clearer
distinction between the pre- and post-treatment groups treated with toxic levels of simvastatin. Through multivariate
statistical analysis, we identified marker metabolites associated with the toxicity. Importantly, we observed that the
treatment group could be further categorized into two subgroups based on the NMR profiles: weak toxicity (WT) and high
toxicity (HT). The distinction between these two groups was confirmed by the enzyme values and histopathological exams.
Time-dependent studies showed that the toxicity at 10 days could be reliably predicted from the metabolic profiles at 6
days.
Conclusions/Significance: This metabonomics approach may provide a non-invasive and effective way to evaluate the
simvastatin-induced toxicity in a manner that can complement current measures. The approach is expected to find broader
application in other drug-induced toxicity assessments.
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Introduction
Simvastatin is among the most prescribed drugs in western
countries, and reduces morbidity and mortalityfromcoronary heart
diseases [1]. It inhibits the enzyme 3-hydroxy-3-methylglutaryl co-
enzyme A (HMG-CoA) reductase, the rate-limiting step in
cholesterol biosynthesis [2,3,4]. The inhibition of HMG-CoA
reductase induces depletion of intracellular sterols, up-regulating
low-density lipoprotein (LDL) receptors, principally in the liver,
with subsequent increased uptake of cholesterol-containing lipo-
proteins. In addition to their lowering effects on cholesterol levels, a
numberofother clinicalbenefits ofstatinshave been recognized [5].
Although statins are generally well tolerated, they do have side-
effects. The most common adverse reaction is myopathy [6]. The
clinical manifestations of statin-associated myopathy include pain
and muscle weakness, with a prevalence of 10%–15% [7]. While
the mechanisms of simvastatin-induced myopathy have not been
fully elucidated, it is likely that simvastatin induces myopathy by
disrupting isoprenoid intermediates in the cholesterol synthesis
pathway. Its effects on muscle range in severity from myalgia and
limb weakness to myopathy, often accompanied by elevated serum
creatinine kinase (CK), or more pronounced skeletal muscle
breakdown, in which the release of myoglobin can cause renal
damage. It has been reported that the development of myopathy
follows a characteristic pattern of elevated serum CK and skeletal
muscle necrosis [8,9,10].
Simvastatin has also been reported to cause adverse effects in
liver due to cellular damage. The incidence of liver function
abnormality increases approximately 4- to 5-fold with increasing
dose of simvastatin [11]. In addition, Clarke et al. reported that
simvastatin might cause hepatitis, cholestatic jaundice, cirrhosis,
hepatic failure, and hepatic necrosis in some patients [12]. In this
report, atorvastatin and pravastatin also caused similar adverse
effects with transient increases in serum transaminases. However,
there are relatively few studies on liver toxicity and the associated
mechanism by statin treatment.
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e16641Metabonomics is a global metabolite profiling approach for
biological samples, particularly, biofluids. Since it involves a large
quantity of data, it is often combined with multivariate statistical
analysis in order to efficiently assess principal factors contributing
to the phenotypic changes. It can be readily applied to monitor the
changes in metabolite concentration and profiles in response to
non-physiologic challenges such as drugs or toxins [13,14]. Such
studies can also provide information about the sites and basic
mechanism of toxicity, as well as potential metabolic biomarkers
[15] which can be used for safety evaluation processes [16].
Recently, metabonomics techniques have shown its utility in
predicting drug-induced toxicity based on pre-dose metabolic
profiles [17,18]. For metabonomics studies, it is desirable to obtain
broad coverage of the metabonome to facilitate the discovery of
potential biomarkers. Therefore,
1H Nuclear Magnetic Resonance
(NMR) spectroscopy of biofluids has been the method of choice
due to its superb reproducibility and quantitativeness
[19,20,21,22]. In terms of biofluid samples, urine is one of the
major targets, as it is a complex biological sample containing a
large number of endogenous metabolites reflecting the metabolic
state of an organism [23]. In addition, urine collection is both
simple and non-invasive, making it a preferred sample for
monitoring metabolic biomarkers.
In this study, we evaluated the applicability of the NMR-based
metabonomics approach in assessing simvastatin-induced toxicity.
We also sought to identify non-invasive urinary biomarkers. Our
results showed that
1H-NMR-based metabonomics approach is
significant and sensitive enough to complement conventional
biochemical enzyme markers (AST, ALT, and CK) in evaluating
the side effects of simvastatin.
Results
Serum biochemical parameters
To investigate the toxic effects of simvastatin, we first performed
well-established biochemical enzyme tests for AST, ALT, and CK.
We selected these enzymes because simvastatin-induced toxicity has
been reported for liver and muscle. The values from the untreated
group were as follows: AST, 107.5067.78; ALT, 29.6761.91; CK,
789.67652.10, which are within normal ranges routinely observed
Figure 1. Changes of body weight and biochemical parameters of each rat after simvastatin treatment. Blood samples were collected
after 10 days of simvastatin treatment (80 mg/kg). Serum alanine transaminase (ALT), aspartate transaminase (AST), and plasma creatinine kinase (CK)
activities were measured using commercial kits employing spectrophotometric assays. All biomarkers were analyzed at Inha University Hospital
(Incheon, Korea).
doi:10.1371/journal.pone.0016641.g001
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PLoS ONE | www.plosone.org 2 February 2011 | Volume 6 | Issue 2 | e16641Figure 2. Representative
1H NMRspectra of urinefrom animals before andafter simvastatin treatment. The spectrum before the simvastatin
treatment is at the top, and that after the treatment is at the bottom. Metabolite peaks were assigned using Chenomx (Spectral database; Edmonton,
Alberta, Canada). The spectra were taken for urine samples containing 150 mM phosphate (pH 7.4) and 0.025% TSP as a chemical shift reference.
doi:10.1371/journal.pone.0016641.g002
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PLoS ONE | www.plosone.org 3 February 2011 | Volume 6 | Issue 2 | e16641Figure 3. Differentiation of pre- and post-treatment groups using multivariate analysis. Orthogonal projections to latent structure-
discriminant analysis (OPLS-DA) score plot of the pre- and post-groups. For the post-treatment group, urine samples collected after 10 days of
treatment were used. Black squares: pre-treatment samples; Red circles: post-treatment samples. The model was established using one predictive and
one orthogonal component.
doi:10.1371/journal.pone.0016641.g003
Figure 4. Signals contributing to the differentiation of pre- and post-treatment groups. S-plot analysis representing the highest
contributing signals for the pre- and post-groups. The pp represents modeled covariation, and p(corr)p represents modeled correlation. Potential
marker signals that are significantly biased across the two groups are enclosed in dotted boxes.
doi:10.1371/journal.pone.0016641.g004
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AST activity was increased by 2.7-fold (284.17687.58, p,0.02) and
the ALT activity by 4.0-fold (115.736175.57, p,0.03) in the
simvastatin-treated group indicating drug-induced liver toxicity. In
comparison, the CK level, which is often associated with muscle
toxicity in humans, was not significantly different (1298.826396.52,
p.0.16). However, for all three enzymes, there were large variations
among the individual animals. Some animals showed pronounced
toxicity, while others exhibited relatively low toxicity, and the trends
did not match among the enzyme classes (Fig. 1). For example,
simvastatin treatment seemed to be highly toxic to some subjects (A-
9,A-10,A-11)inallfourfactors,whileitseemed tobeweaklytoxicto
others (A-1, A-5, A-6, A-8) (See Fig. 1). In addition, some subjects
showed quite different results depending on the criteria. For
example, A-3 showed highly toxic response in terms of the change
ofbodyweight andAST,butitshowedonlyweaktoxicityintermsof
ALT and CK. In addition, the values obtained from simvastatin-
treated animals were much more variable within each of the enzyme
classes.Therefore,itwasnotimmediatelyclearwhichenzymeclasses
or values should be used to decide the toxicity manifestation.
NMR Spectroscopy of urine samples
With the variable results from the biochemical data, we
explored toxicity evaluation by metabonomics using urine
samples. Nuclear magnetic resonance (NMR)-based metabonomic
analysis of urine samples offers several advantages in that urine
samples can be obtained non-invasively and that they reflect more
systemic effects than individual biochemical enzymes [14,24,25].
Moreover, NMR spectroscopy can give structural information
about the potential biomarkers. Representative
1H NMR spectra
of urine from animals before and after simvastatin treatment are
shown in Fig. 2. We identified a number of constituents in the
urine as a preliminary step in finding marker metabolites.
Although there were some apparent differences between these
representative spectra based on simple visual inspection, they were
not consistent across all samples. Therefore, we applied a
multivariate statistical method to analyze the spectra in a more
holistic way and to identify signals that can efficiently differentiate
the groups.
OPLS-DA Multivariate analysis
Since we observed intra-group variation, we analyzed the data
with the OPLS-DA multivariate approach, which can separate
groups in the presence of large structured noise [26,27]. The
differentiation model for distinguishing the animals before (pre-
group) and after (post-group) simvastatin treatment was built using
one predictive and four orthogonal components (Fig. 3). The
model had an overall goodness of fit, R
2(Y), of 96% and an overall
cross-validation coefficient, Q
2(Y), of 68%. Out of the overall
R
2(X) value of 0.83, 63% was structured, but uncorrelated to the
response, and 20% was predictive, that is, responsible for the class
separation. The resulting score plot shows that the pre- and post-
groups can be clearly differentiated by the first predictive
component derived from the NMR spectral variables. This
differentiation was thought due to the liver toxicity, as the average
values of AST and ALT were statistically higher in the simvastatin
treated group (see Table S1).
One advantage of the metabonomics approach is that it can
give marker metabolites that contribute to the differentiation.
Therefore, we explored the orthogonal partial least-squares
discrimination analysis (OPLS-DA) model to identify the metab-
olites that are characteristic of the group with toxic responses. We
constructed an S-plot that can show the modeled covariation, pp,
with the modeled correlation, p(corr)p, in one graph. The resulting
S-plot shows that most of the markers for the post-group have
signals in the 3.0–5.4 ppm region (Fig. 4). In contrast, the markers
for the pre-group have signals in the 2.4–2.6 ppm region. Based
on the urine constituents identified above, the marker signals for
the post-groups belong to 2-oxoglutarate (3.03 ppm), trimethyl-
amine-N-oxide (3.29 ppm) and allantoin (5.39 ppm). To demon-
strate the actual biased distribution of the toxicity markers found
by the multivariate analysis, we compared the relative amounts of
the markers in both of the groups. Fig. 5 shows that the levels of
the toxicity markers were significantly higher in the post-group. All
of the markers showed strong statistical significance with p-values
of less than 0.01 obtained from Student’s t-test.
Different toxic responses within the post-group
In examining the NMR multivariate data in more detail, we
found that the post-group can be divided into two subgroups along
the Y axis of the plot (See the dotted red lines in Fig. 3), whereas
the pre-group is clustered tightly without such intra-group
separation. This indicates that there could be differences in the
individual toxicity levels in the post-group. To examine this
possibility, we re-analyzed the biochemical enzyme data for these
two subgroups. Fig. 6 shows that there are significant differences in
the enzyme values between the two subgroups, consistent with the
NMR-based analysis. In addition, the subgroup with higher CK
values showed significantly different values from the control group,
despite the fact that the post-group as a whole did not show such
difference (Table S1). Based on the results, we designated the
subgroups as WT and HT groups.
Histopathological confirmation of the toxicity subgroups
To examine the difference in the toxicity at the tissue level, we
obtained the histopathological data on liver tissues. H&E staining
of the liver showed that the control group had mostly intact nuclei
and normal cell shapes. In addition, the hepatic lobular structure
and portal tract were well preserved without inflammation or
necrosis (Fig. 7). The lobules in the HT group, however, showed
increased Kupffer cell density and inflammatory cell infiltration.
Moreover, the hepatocytes showed occasional acidophilic degen-
eration, necrosis or swelling, and regeneration activity, which
suggest significant cellular damage. In comparison, the WT group
showed similar characteristics in lobular structures and inflamma-
tion status to the control group. These data validate the
categorization of the post-group into two subgroups and prove
the effectiveness of the NMR metabonomics approach.
Time dependent toxicity according to urine NMR analysis
To investigate how effectively these subgroup differences can
be detected, we obtained urine at several time points and
analyzed the corresponding NMR spectral data. The results in
Fig. 8 show that the difference is not clear before or 3 days after
the drug treatment (black or red symbols, respectively). In
comparison, the WT and HT group diverged from 6 days after
the treatment, following different paths thereafter and ending up
in very distinct parts of the two-dimensional reduced-dimension
Figure 5. Levels of the marker signals in the pre- and post-treatment groups. Student’s t-test of the relative distribution of the marker
signals for the pre- and post-treatment group. The resulting p-values are indicated, and all the signals showed statistical significance with p,0.01. (A)
Top: 5.3916 ppm; (B) Middle: 3.0319 ppm; (C) Bottom: 3.2893 ppm.
doi:10.1371/journal.pone.0016641.g005
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differentiate between WT and HT groups as early as 6 days after
the treatment. Equally interestingly, after 10 days, the Euclidean
distance between the WT and pre-group was much smaller than
that between the HT and pre-group. In addition, the final
coordinate of the WT group after 10 days was even closer to the
pre-group than those after 3 and 6 days. These findings suggest
that the urine profile of the WT group after 10 days is more
similar to that from pre-group than that from the 3 or 6 days,
consistent with the biochemical toxicity and histopathological
results.
Discussion
Simvastatin is relatively safe in normal dosage. In previous case
studies, however, it has been reported to be hepatotoxic and
myotoxic in cumulative high doses. In order to investigate the
toxic effects of simvastatin, we first performed well-established
biochemical enzyme tests for AST, ALT, and CK. In terms of the
evaluation of toxicity, the values from just one or two biological
surrogate serum enzymes were not decisive. In our results, the
changes in body weight, AST, ALT, and CK were not correlated
with each other in all subjects. Therefore, it was not easy to obtain
consistent indications regarding the toxicity of simvastatin in these
subjects. In comparison, the metabonomics studies provided a
clearer distinction of the toxicity, new toxicity markers, and further
differentiation of the WT and HT groups.
From the analysis of NMR patterns before and after treatment
with simvastatin, three new biological markers were discovered:
allantoin, 2-oxoglutarate, and trimethylamine-N-oxide. These
markers were all increased by simvastatin treatment. Allantoin is
formed by nonenzymatic oxidation of urate, and is reported to be
a possible indicator of free radical damage [28]. Therefore, higher
levels of allantoin in the HT group suggest that simvastatin may
induce oxidative stress. 2-oxoglutarate is generated from isocitrate
through oxidative decarboxylation in the tricarboxylic acid cycle.
Another round of oxidative decarboxylation transforms it into
succinate and also generates GTP. Both of these decarboxylation
steps generate NADH, a key molecule in oxidation-reduction
reactions. Therefore, 2-oxoglutarate is intimately involved in the
cellular detoxification of oxidative damage. The changes in its
level in the HT group suggest that the observed simvastatin-
induced toxicity is related to oxidative stress, consistent with our
interpretation of the changes in allantoin levels. Trimethylamine-
N-oxide (TMAO) is an oxidation product of trimethylamine and is
also involved in the oxidation-reduction reactions for nucleotide
metabolism. High levels of TMAO have been implicated in
inflammatory responses present in Rheumatoid arthritis [29].
Overall, these markers suggest that the simvastatin-induced
toxicity seems to mainly stem from oxidative stress-related
inflammatory responses. In this sense, it is interesting to note that
a similar drug, atorvastatin, increased the urine levels of proline
and 3-ureidopropionic acid that are associated with oxidative
toxicity in rat system [30] [31,32].
For the specific oxidative pathway, simvastatin might decrease
the prodution of Coenzyme Q10 (CoQ10). This is feasible because
simvastatin inhibits HMG CoA reductase that generates meval-
onate which, in turn, is a precursor for CoQ10. CoQ10, as an
antioxidant, has membrane stabilizing effects and is important for
cellular mitochondrial respiration, essential for energy production
in organs[33,34]. A previous study showed that simvastatin
induced DNA oxidative stress in liver cells and, CoQ10 treatment
protected liver cells from simvastatin’s toxic effect [35]. In
addition, CoQ10 treatment improved oxidative stress response
by increasing NADPH-CoQ reducates in liver injury induced by
simvastatin [36]. These results are consistent with the possible
involvement of simvastatin in the antioxidative pathway of
CoQ10.
Our results provide several practical applications of the NMR-
based metabonomics approach in evaluating simvastatin toxicity.
First, as the presence of the WT and HT subgroups and their
difference from the pre-group were not immediately apparent
from only the biochemical data, the metabonomics approach
seems to allow more detailed assessment of the toxicity than
conventional markers. It should be noted that the urine profile
measured by NMR not only distinguished between the subgroups,
but also gave a measure of the degree of toxicity in the forms of the
direction and the Euclidean distance of a particular group from
the control group. The validity of the results was confirmed by its
consistency with the biochemical and histopathological data.
Second, the metabonomics data may allow earlier detection of the
toxicity, enabling the prediction of later toxicity. Our data showed
that the toxicity at 10 days of treatment was reliably correlated
with that at 6 days. As the HT group showed more pronounced
toxicity than the WT group, the urine metabolite profile might be
Figure 6. Difference between WT and HT subgroup: biochemical data. The WT and HT subgroups among the simvastatin treated animals
were categorized according to the OPLS-DA model as described in the text. Average values of AST, ALT and CK levels of each group after 10 days of
treatment are plotted along with the standard deviation. Student’s t-test was also performed and the resulting p values are also indicated. (A) AST; (B)
ALT; (C) CK.
doi:10.1371/journal.pone.0016641.g006
Figure 7. Histopathological analysis of liver sections. The liver tissues were collected after 10 days of simvastatin treatment. The tissues were
fixed in 10% formaldehyde, and then stained using Hematoxylin and Eosin (H&E). Original magnification 6400. Control, control group; WT, weak
toxicity group; HT, high toxicity group.
doi:10.1371/journal.pone.0016641.g007
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before it causes significant and/or irreversible damages. Third, the
NMR urine profile can provide toxicity data in a completely non-
invasive manner. Although the histopathological method is the
gold standard in toxicity assessment, it requires an invasive biopsy
and can sometimes cause unintended complications, for example,
infections during the sampling. Although the AST, ALT, and CK
values can be measured in serum samples, which are considered
minimally invasive, the blood can only be collected in a hospital
setting by appointment with specialized personnel. In contrast,
urine can be collected without these limitations. Therefore, the
metabonomics approach has added convenience in addition to its
merits in toxicity assessment.
Taken together, NMR-based metabolite profiling combined
with multivariate analysis may provide new criteria for evaluating
the simvastatin-induced toxicity that can complement currently
available biochemical or histopathological measures. With the
convenience of sample collection, the possibility of predicting the
future responses, and the technical robustness, this approach is




Simvastatin USP was obtained from Biocon (Bangalore, India).
Simvastatin was formulated as a suspension in 0.5% hydroxypro-
pyl methylcellulose and 0.1% w/v polysorbate 80.
Animals and treatments
Animal care and experimental procedures were conducted in
accordance with the Guide for Animal Experiments by the
Korean Academy of Medical Sciences. Female Wistar rats (6
weeks) were obtained from ORIENT-BIO Laboratory Animal
Research Center Co., Ltd. (Gyeonggi-do, Korea). Animals were
kept on standard rat chow with free access to tap water in a
temperature- and humidity-controlled animal house under 12 h
light–dark cycles. Eighteen rats were divided into two groups
(control and simvastatin groups). The simvastatin group (n=12)
was orally administered simvastatin (formulated as a suspension in
0.5% hydroxypropyl methylcellulose and 0.1% w/v polysorbate
80) at a dose of 80 mg/kg of body weight for 10 days. The control
group (n=6) was treated with volumes of vehicle solution (0.5%
hydroxypropyl methylcellulose and 0.1% w/v polysorbate 80)
equivalent to those given to the simvastatin group. Individual pre-
dose (24 h) and post-dose (3, 6 and 10 days) urine samples were
collected into an ice-cooled jar on the metabolic cages. The pooled
urine samples were frozen and stored at 280uC for subsequent
analysis. All animal experiments were conducted at the Inha
University Medical School Animal Experiment Center (Incheon,
Korea). At the end of the 10 days, all rats were sacrificed by ether
anesthesia. Blood samples for biochemical analyses were obtained
from the hearts. The liver specimens were immediately fixed in
10% neutral buffered formalin for histopathological studies.
NMR Spectroscopic Analysis of Urine
For NMR analysis, urine samples were thawed at room
temperature, and 500 ml of urine was mixed with 50 mlo f
phosphate buffer (1.5 M K2HPO4/1.5 M NaH2PO4, pH=7.4).
Samples were allowed to stand for 10 min and then centrifuged at
13,000 rpm for 10 min to remove insoluble material. 500 mlo f
supernatants were placed in a 5 mm NMR tube containing 50 ml
D2O and sodium-3-trimethylsily-[2,2,3,3-
2H4]-1-propionate (TSP,
0.025%, w/v) as internal standard reference (0.00 ppm).
Biochemical analyses of serum
Blood was drawn into lithium heparin tubes after euthanasia for
evaluation of serum alanine transaminase (ALT), aspartate
Figure 8. Time course of the urine metabolite profile. Urines collected at specified time points during the simvastatin treatment (80 mg/kg)
were analyzed by NMR and OPLS-DA. The coordinates of each time point represent the average score values from the multivariate analysis. The
whiskers represent one standard deviation. Open symbols represent the HT group and the filled symbols WT group. Each time point is represented
by different colored symbols: Pre, black squares; 3 Day, red circles; 6 Day, blue diamonds; 10 Day, green triangles. The transitions for the 6 day to 10
day are specified by arrows. Others are not indicated to simplify the figure, but can be easily traced by following the open or filled symbols,
respectively.
doi:10.1371/journal.pone.0016641.g008
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(spectrophotometric assay). Out of the 12 simvastatin-treated
animals, we could not obtain the blood for one animal due to its
death during the collection procedure. Therefore, biochemical
markers were obtained for 11 animals. All biomarkers were
analyzed at Inha University Hospital (Incheon, Korea).
Liver histopathology
After fixation for 48 hours, liver tissues were embedded in
paraffin according to routine procedures. Five-mm thick sections
were cut and stained with hematoxylin-eosin (H&E) for histopath-
ological evaluation. Two expert pathologists at Inha University
Hospital blindly analyzed the tissue slices.
NMR measurement
One-dimensional spectra of the urine samples were measured
with an NMR spectrometer (Bruker Biospin, Avance 500)
equipped with a triple-resonance cryogenic probe, operating at a
proton NMR frequency of 500.13 MHz. We also used 500 MHz
machine (VNMRS500) at Varian Inc. Korea’s facility for
metabolite identification. The acquisition parameters were
essentially the same as those previously reported [27,37,38],
except the number of scans (64). The spectra were referenced
against the TSP signal. The metabolites were identified using
Chenomx (Spectral database; Edmonton, Alberta, Canada) by
fitting the experimental spectra to those in the database. This
study was conducted at the NMR facility at the Korea Basic
Science Institute, which is supported by the Bio-MR Research
Program of the Korean Ministry of Science and Technology
(E29070).
Multivariate data analysis
All the obtained time domain NMR data were Fourier
transformed, phase corrected, and baseline corrected manually.
The resulting frequency domain data were binned at a 0.043 ppm
interval to reduce the complexity of the NMR data for pattern
recognition. The signals were normalized against total integration
values and 0.025% TSP, and then converted to an ascii text file.
The region corresponding to water (4.6–5.0 ppm) was removed
from all spectra. The binning, normalization, and conversion were
done using Perl software written in-house. The resultant data sets
were then imported into SIMCA-P version 11.0 (Umetrics, Umea ˚,
Sweden) and mean-centered with Pareto scaling for multivariate
statistical analysis. Orthogonal projections to latent structure-
discriminant analysis (OPLS-DA) was performed with one
predictive and four orthogonal components.
Supporting Information
Table S1 Change of body weight and biochemical
parameters of control and simvastatin treatment groups
(averages and student’s t-test). Values are expressed as mean
6 SD. ALT, alanine aminotransferase; AST, aspartate amino-
transferase; CK, creatinine kinase.
(DOC)
Table S2 Change of body weight and biochemical
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